Abstract
Background Long COVID is characterized by persistent symptoms affecting one or more organ systems for at least 3 months following a SARS-CoV-2 infection. The pathophysiologic mechanisms of this complex disease are poorly understood. Beyond the described symptoms of fatigue, dyspnea, myalgias, among others, Long COVID can affect the patient’s ability to work and function in society compared to their baseline. Frailty is defined as the decline of physiologic reserve that leads to increased vulnerability to stressors and poor health outcomes. Our study aimed to examine the characteristics of frailty seen in patients with Long COVID compared to the frailty seen in aging patients with multimorbidity.
Methods This is a retrospective cohort study conducted in the Miami Veterans Affairs Medical Center (VAMC). The data used to calculate the Fried phenotype through the Johns Hopkins frailty calculator was collected from two separate clinics, a Long COVID clinic and a Geriatric Frailty clinic. We obtained the VA Frailty Index from VA CDW (Corporate Data Warehouse).
Results We included 106 patients from the Long COVID clinic and 97 from the frailty clinic. Patients from the Long COVID clinic were significantly younger than those from the frailty clinic (60±12.6 vs.. 79.8±5.8, p<0.01). In the standard frailty group, weakness and slowness were the predominant features present in both the frail and pre-frail groups, with increasing exhaustion and lower activity in the frail group. Patients with frailty in the Long COVID group experienced exhaustion and low activity at a higher rate than those in the Geriatric frailty clinic.
Conclusions Long COVID may predispose patients to develop a subtype of frailty (“post-viral frailty”) that presents with a higher frequency of exhaustion and low activity. This frailty appears phenotypically different from the frailty encountered in geriatric patients with multimorbidity, which presents more often with slowness and weakness as the initial drivers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of the Miami Veterans Affairs Healthcare System (4 June 2021, reference number 1592780-1). The IRB granted a waiver for informed consent. The data was fully anonymized according to VHA standards prior to analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets presented in this article are not readily available because of the Department of Veterans Affairs data policies. Requests to access the datasets should be directed to the Department of Veterans Affairs
